An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification dated December 17, 2021 indicating that Tolefi SA and related persons have crossed together the statutory threshold of 20%, holding 18,65% of the voting rights of the company as of 8 December 2021.
Content of the Notification:
Reason of the Notification:
Downward passive crossing of the 20% threshold
Downward passive crossing by persons acting in concert
Notification by:
Persons acting in concert
Persons subject to the notification requirement:
Tolefi SA, Chaussée de Waterloo 1589D, 1180 Uccle
Serge Goblet Isabelle Thoumyre Jérôme Goblet Jean-Daniel Goblet
Transaction date
December 8, 2021
Threshold that is crossed (in %)
20
Denominator
24.961.981
Notified details:
A) Voting Rights
Previous
notification
After the Transaction
#of voting rights
# of voting rights
% of voting rights
Holders of voting rights
Linked to the
securities
Not linked to the
securities
Linked to the
securities
Not linked to the
securities
Tolefi SA
4.591.402
4.591.402
18,39%
Serge Goblet
56.180
56.180
0,23%
Isabelle Thoumyre
7.300
7.300
0,03%
Jérôme Goblet
250
250
0,00%
Jean-Daniel Goblet
384
384
0,00%
TOTAL
4.655.516
4.655.516
18,65%
Chain of controlled undertakings through which the holdings is effectively held
Tolefi SA is 100% controlled by Serge Goblet, Isabelle Thoumyre, Jérôme and Jean-Daniel Goblet.
Miscellaneous
The Press Release may be consulted on the website of Celyad Oncology via this link.
The notification can be consulted on the website if Celyad Oncology via thislink.
Contact person(s):
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.
About Celyad Oncology SA
Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.
Forward-looking statements
This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the clinical activity and safety and tolerability of CYAD-211 and expectations regarding enrollment and the announcement of additional clinical data, and the clinical activity and safety and tolerability of the CYAD-02 and CYAD-101 programs. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
founded in 2007, celyad is a clinical-stage biopharmaceutical company that leverages unique know-how in taking cell-based therapies from bench to phase iii, as well as the manufacturing and logistical infrastructure for such complex products. celyad builds it business model on partnering with prominent research institutions such as dartmouth college, and develops those programs from bench to commercial applications. the company is currently developing clinical programs in immuno-oncology, testing natural killer receptors t-cells (nkr-t cells) for cancer treatment. a unique approach that has the potential to target and destroy a vast majority of tumor types. celyad is listed on euronext brussels, euronext paris and on nasdaq (cyad).